ArticleBMC cancer2025
Circulating Hsp70: a tumor biomarker for lymph node metastases and early relapse in thoracic cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Association of Preoperative Circulating Hsp70 Levels with Event-Free Survival in Thoracic Oncology.Cancers · 2026Article
- Exogenous Heat Shock Proteins in Oncology: Biological Roles and Clinical Implications.Cancers · 2026Review
- Heat Shock Proteins as Cancer Biomarkers: From Mechanism to Clinical Application.Molecular diagnosis & therapy · 2026Review
- Circulating Hsp70 Reflects Tumor Burden and Stage-Dependent Disease Progression Across Multiple Solid Tumor Entities.Cancers · 2026Article
- Fluorescence Immunosensor with Phage Antibodies for Heat Shock Protein 70 Detection.Biosensors · 2026Article
- HSP70-mediated regulation of P-glycoprotein SUMOylation suppresses ferroptosis to drive thermoresistance in non-small cell lung cancer.Frontiers in immunology · 2026Article
- A narrative review of the early diagnosis and treatment of idiopathic pulmonary fibrosis with lung cancer.Journal of thoracic disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeat shock protein 70 (Hsp70) which is frequently overexpressed in many different cancer types is also present on the plasma membrane of tumor but not normal cells. The intensity of membrane-expressed Hsp70 (mHsp70) is associated with disease progression and treatment resistance. It has also been shown that Hsp70 can be actively released into the circulation by mHsp70 positive, viable tumor cells in the form of extracellular lipid microvesicles expressing mHsp70, the levels of which might therefore act as a potential biomarker for tumor aggressiveness in lung malignancies.
methodsExtracellular Hsp70 (eHsp70) was measured in the plasma of patients with non-small cell lung cancer (n = 178, NSCLC) and lung metastases of extrathoracic tumors (n = 35) prior to surgery using the Hsp70-exo ELISA which detects microvesicle-associated eHsp70 and the patient`s immunophenotype was determined by flow cytometric analysis of the corresponding peripheral blood lymphocytes.
resultseHsp70 values were significantly higher in patients with NSCLC than in healthy individuals, with no differences between adeno and squamous cell carcinomas. Levels of circulating eHsp70 which are associated with the Programmed cell death protein 1 (PD-L1) status, gradually increased from early stage to metastatic disease, and patients with lymph node metastases in surgically treatable NSCLC had significantly higher eHsp70 levels than nodal negative patients. In all tumor stages, total lymphocyte counts were significantly reduced and immunoregulatory T (Treg) cell counts were increased compared to healthy controls. Lower CD4 + T helper cell and higher CD3-/CD56+/CD94+/CD69+/NKp30+/NKp46 + NK cell ratios were only found in patients with thoracic metastases of other primary tumors. An early relapse after complete resection with curative intent correlated with significantly elevated eHsp70 levels which were measured prior to surgery, in all thoracic cancer patients.
conclusionsIn summary, we propose circulating eHsp70 levels before any treatment as a predictive biomarker for the presence of lymph node metastases and early therapy failure in patients with thoracic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.